⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplemental Figure 1 from Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients

Cloud P. Paweletz Grace A. Heavey Yanan Kuang Emily Durlacher Thian Kheoh Richard C. Chao Alexander I. Spira Konstantinos Leventakos Melissa L. Johnson Sai‐Hong Ignatius Ou Gregory J. Riely Kenna Anderes Wenjing Yang James G. Christensen Pasi A. Jänne

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplemental Figure 1: Quantitative concordance between NGS and ddPCR KRASG12C results. ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Paweletz et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523a3d https://doi.org/10.1158/1078-0432.27032146.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 1 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients2024
2Supplemental Figure 3 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients2024
3Supplemental Figure 3 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients2024
4Supplemental Figure 4 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients2024
5Supplemental Figure 4 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients2024